VCYT · Company research
Veracyte, Inc. (VCYT): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
28records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Researchers will present first evidence that a prostate test predicts who benefits from an added drug. - Stock Titan | Researchers will present first evidence that a prostate test predicts who benefits from an added drug. Stock Titan | View source ↗ | Stock Titan | Oct 19, 2026 | neutral | 0 | 0.6 |
| Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo! Finance Canada | Veracyte, Inc. (VCYT) Stock Forecasts Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 19, 2026 | neutral | 0 | 0.6 |
| A breast cancer test could spare chemotherapy for more than two-thirds of clinically high-risk patients - Stock Titan | A breast cancer test could spare chemotherapy for more than two-thirds of clinically high-risk patients Stock Titan | View source ↗ | Stock Titan | Oct 16, 2026 | neutral | 0 | 0.6 |
| Veracyte (NASDAQ:VCYT): Affordable Growth Backed by Strong Fundamentals - ChartMill | Veracyte (NASDAQ:VCYT): Affordable Growth Backed by Strong Fundamentals ChartMill | View source ↗ | ChartMill | Oct 13, 2026 | neutral | 0 | 0.6 |
| Cathie Wood’s Ark weekly recap: cuts SpaceX exposure alongside HOOD, TER, boosts CRWV, VCYT (ARKK:BATS) - Seeking Alpha | Cathie Wood’s Ark weekly recap: cuts SpaceX exposure alongside HOOD, TER, boosts CRWV, VCYT (ARKK:BATS) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 12, 2026 | neutral | 0 | 0.6 |
| Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo! Finance Canada | Veracyte, Inc. (VCYT) Stock Forecasts Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 9, 2026 | neutral | 0 | 0.6 |
| Is Veracyte Inc (VCYT) Overvalued After 3.7% Rally? GF Value Say - GuruFocus | Is Veracyte Inc (VCYT) Overvalued After 3.7% Rally? GF Value Say GuruFocus | View source ↗ | GuruFocus | Oct 9, 2026 | neutral | 0 | 0.6 |
| Veracyte (VCYT) Stock Still Looks Cheap As Its 107% Run Continues - Yahoo Finance | Veracyte (VCYT) Stock Still Looks Cheap As Its 107% Run Continues Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo Finance | Veracyte, Inc. (VCYT) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| Reasons to Hold HealthEquity Stock in Your Portfolio for Now | HealthEquity reported solid fiscal Q2 2027 results with revenues up 7.6% and adjusted EPS rising 14.8%. HSA assets reached $37.9 billion with investments growing 20% year-over-year, while AI implementation reduced service costs and improved margins to 48%. The company raised fiscal 2027 adjusted EBITDA guidance to $628-$636 million. However, ongoing cybersecurity litigation and regulatory inquiries from a fiscal 2025 incident pose risks to future growth and profitability. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies | Veeva Systems' Data Quality System (DQS) platform has expanded its reach to support data cleaning across over 1,000 clinical studies involving more than 1 million subjects, generating 500,000+ automated queries. The platform's integration with AI, CTMS, and Study Builder Agent is expected to drive deeper customer engagement and recurring revenue growth in the life sciences software market. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Reasons to Add Globus Medical Stock to Your Portfolio Now | Globus Medical (GMED) reported strong Q2 2026 performance with musculoskeletal revenues rising 7.5% and base business sales up 10.9%. The company continues to gain market share through product innovation, with over 60 development projects underway. However, foreign exchange volatility remains a concern. GMED maintains a debt-free balance sheet with $507.7 million in cash, supporting continued R&D and expansion investments. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Charles River Gains 75.8% in a Year: What's Driving the Rally? | Charles River Laboratories (CRL) has outperformed the market with a 75.8% share price increase over the past year, driven by strong Research Models and Services (RMS) prospects and adoption of new approach methodologies. However, the company faces headwinds from uneven demand recovery across client segments, with small and midsized biotech revenues flat and currency fluctuations impacting reported growth. The company maintains a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.75 | 1 |
| Is This the Right Time to Add TMO Stock to Your Portfolio? | Thermo Fisher Scientific (TMO) is strengthening growth through innovation, AI investments, and strategic acquisitions expected to contribute $1.6 billion in revenues and 32 cents to adjusted EPS in 2026. The company expects organic revenue growth at 3%-4% for 2026 supported by broad-based end-market improvements. However, risks from macroeconomic uncertainty, inflation, geopolitical disruption, and unfavorable currency movements could weigh on results and margins. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Fund Update: New $90.0M $VCYT stock position opened by CONGRESS ASSET MANAGEMENT CO - Quiver Quantitative | Fund Update: New $90.0M $VCYT stock position opened by CONGRESS ASSET MANAGEMENT CO Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 6, 2026 | neutral | 0 | 0.6 |
| Fund Update: New $90.0M $VCYT stock position opened by CONGRESS ASSET MANAGEMENT CO - Quiver Quantitative | Fund Update: New $90.0M $VCYT stock position opened by CONGRESS ASSET MANAGEMENT CO Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 6, 2026 | neutral | 0 | 0.6 |
| Is It Prudent to Add Teleflex Stock to Your Portfolio Now? | Teleflex (TFX) reported Q2 2026 Vascular revenue growth of 9% driven by central access and hemostatic product demand, with Asia revenues jumping 59.5%. However, tariffs and acquisition costs pressured margins, with adjusted operating margin declining 520 basis points. The company improved its balance sheet with pro forma net leverage at 1.9X after debt repayment. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.75 | 1 |
| Is It Prudent to Add Teleflex Stock to Your Portfolio Now? | Teleflex (TFX) reported Q2 2026 Vascular revenue growth of 9% driven by central access and hemostatic product demand, with Asia revenues jumping 59.5%. However, tariffs and acquisition costs pressured margins, with adjusted operating margin declining 520 basis points. The company improved its balance sheet with pro forma net leverage at 1.9X after debt repayment. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.75 | 1 |
| Veracyte (VCYT) Could Be 22% Undervalued After New Decipher Phase III Data - Yahoo Finance | Veracyte (VCYT) Could Be 22% Undervalued After New Decipher Phase III Data Yahoo Finance | View source ↗ | Yahoo Finance | Oct 2, 2026 | neutral | 0 | 0.6 |
| Neogen Stock Rallies 83% YTD: What's Driving the Surge? | Neogen (NEOG) shares have surged 83% year-to-date, outperforming the S&P 500, driven by strong Food Safety segment growth with core revenue increases of 5.8% in Q4 fiscal 2026. The company is expanding manufacturing capabilities following its 3M Food Safety acquisition, planning a 50% increase in R&D spending for fiscal 2027 focused on pathogen detection and sanitation platforms. However, fiscal 2027 EPS is projected to decline 3.1% before recovering with 17.2% growth in fiscal 2028. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 1 | 1 |
| Neogen Stock Rallies 83% YTD: What's Driving the Surge? | Neogen (NEOG) shares have surged 83% year-to-date, outperforming the S&P 500, driven by strong Food Safety segment growth with core revenue increases of 5.8% in Q4 fiscal 2026. The company is expanding manufacturing capabilities following its 3M Food Safety acquisition, planning a 50% increase in R&D spending for fiscal 2027 focused on pathogen detection and sanitation platforms. However, fiscal 2027 EPS is projected to decline 3.1% before recovering with 17.2% growth in fiscal 2028. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 1 | 1 |
| For 44% with low scores, added hormone therapy showed no statistically significant benefit against 10-year cancer spread. - Stock Titan | For 44% with low scores, added hormone therapy showed no statistically significant benefit against 10-year cancer spread. Stock Titan | View source ↗ | Stock Titan | Sep 29, 2026 | neutral | 0 | 0.6 |
| Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains? - Yahoo Finance | Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains? Yahoo Finance | View source ↗ | Yahoo Finance | Sep 25, 2026 | neutral | 0 | 0.6 |
| Eight studies will examine who with prostate cancer may benefit from more treatment - Stock Titan | Eight studies will examine who with prostate cancer may benefit from more treatment Stock Titan | View source ↗ | Stock Titan | Sep 25, 2026 | neutral | 0 | 0.6 |
| A Veracyte (VCYT) director plans a $352,500 share sale after selling 5,000 shares. - Stock Titan | A Veracyte (VCYT) director plans a $352,500 share sale after selling 5,000 shares. Stock Titan | View source ↗ | Stock Titan | Sep 24, 2026 | neutral | 0 | 0.6 |
| Down 30.2% in 4 Weeks, Here's Why Veracyte (VCYT) Looks Ripe for a Turnaround - Yahoo Finance | Down 30.2% in 4 Weeks, Here's Why Veracyte (VCYT) Looks Ripe for a Turnaround Yahoo Finance | View source ↗ | Yahoo Finance | Aug 17, 2026 | neutral | 0 | 0.6 |
| Veracyte (VCYT) Stock Sinks As Profit Strength Meets Reimbursement Doubt - Simply Wall Street | Veracyte (VCYT) Stock Sinks As Profit Strength Meets Reimbursement Doubt Simply Wall Street | View source ↗ | Simply Wall Street | Aug 1, 2026 | neutral | 0 | 0.6 |
| Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report? - Yahoo Finance | Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report? Yahoo Finance | View source ↗ | Yahoo Finance | Jun 4, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.